Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 3597613, 11 pages
Review Article

Advances in Immunotherapy for Glioblastoma Multiforme

1Department of Neurosurgery, Beijing Electric Hospital, State Grid, Beijing 100073, China
2Department of Neurosurgery, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, Hubei 430015, China
3Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China
4Department of Hematology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China
5Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China
6Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

Correspondence should be addressed to Creed Stary; ude.drofnats@yratsc and Xiaoxing Xiong; nc.ude.uhw@gnoixgnixoaix

Received 15 June 2016; Revised 15 January 2017; Accepted 26 January 2017; Published 19 February 2017

Academic Editor: Menaka C. Thounaojam

Copyright © 2017 Boyuan Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma. The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints.